Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control

Journal of Medical Economics

Volumn 18, Issue 2, 2015, Pages 113-125

  Lafeuille, Marie Hélène ^a   Grittner, Amanda Melina ^a   Gravel, Jonathan ^a   Bailey, Robert A ^b   Martin, Silas ^b   Garber, Lawrence ^c   Duh, Mei Sheng ^d   Lefebvre, Patrick ^a  

^a GROUPE D ANALYSE   (Canada)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c Reliant Medical Group   (United States)

^d ANALYSIS GROUP   (United States)

Author keywords

Blood pressure; Canagliflozin; HbA1c; Healthcare costs; LDL C; Sitagliptin; Type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; DIASTOLIC BLOOD PRESSURE; ECONOMIC ASPECT; ELECTRONIC MEDICAL RECORD; FEMALE; GENITAL MYCOTIC INFECTION; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY CONTROL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; URINARY TRACT INFECTION; YOUNG ADULT; ADOLESCENT; BLOOD PRESSURE; COMORBIDITY; COMPLICATION; COMPUTER SIMULATION; COST; DIABETES MELLITUS, TYPE 2; ECONOMICS; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; INSURANCE; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CANAGLIFLOZIN; CHOLESTEROL, LDL; COMORBIDITY; COMPUTER SIMULATION; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; MODELS, ECONOMETRIC; QUALITY INDICATORS, HEALTH CARE; SITAGLIPTIN PHOSPHATE; YOUNG ADULT;

EID: 84923136008     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.980503     Document Type: Article

References (67)

1. American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care 2013;36:1033-46
2. Kim S. Burden of hospitalizations primarily due to uncontrolled diabetes implications of inadequate primary health care in the United States. Diabetes Care 2007;30:1281-2
3. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34(1 Suppl):S11-61
4. Nichols GA, Joshua-Gotlib S, Parasuraman S. Independent contribution of A1C, systolic blood pressure, and LDL cholesterol control to risk of cardiovascular disease hospitalizations in type 2 diabetes: an observational cohort study. J Gen Intern Med 2013;28:691-7
5. Teoh H, Després J, Dufour R, et al. A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care. Diabetes, Obes Metab 2013;15:1093-100
6. Higgins A, Stewart K, Dawson K, et al. Early lessons from accountable care models in the private sector: partnerships between health plans and providers. Health Aff 2011;30:1718-27
7. Centers for Medicare and Medicaid Services. Medicare program: Medicare Shared Savings Program: accountable care organization: final rule. Fed Regist 2011;76:67802
8. RTI International Telligen. Accountable care organization 2012 program analysis, quality performance standard narrative measure specification, final report. Res Triangle Par RTI Int 2011;Dec 12 (RTI Project No. 0213195.000.004)
9. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007;50:2239-44
10. Nathan D, Balkau B, Bonora E, et al. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34
11. The American Diabetes Association, European Association for the Study of Diabetes, International Federal of Clinical Chemistry and Laboratory Medicine, The Internation Diabetes Federation. Consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 2007;30:2399-400
12. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macro-vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
14. The Diabetes Control and Complications Trial Research Group, Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes: four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9
15. Turner RC, Holman RR, Cull CA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
16. Stratton IM, Cull CA, Adler AI, et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006;49:1761-9
17. Estacio R, Jeffers B, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(2 Suppl):B54-64
18. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37:1053-9
19. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-72
20. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421. http://www.ncbi.nlm.nih.gov/pubmed/12485966. Accessed August 1, 2014
21. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with ator-vastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
22. Laakso M, Lehto S, Penttila I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88:1421-30
23. Aneja A, El-Atat F, McFarlane SI, et al. Hypertension and obesity. Recent Prog Horm Res 2003;59:169-205
24. Hamilton CC, Geil PB, Anderson JW. Management of obesity in diabetes mellitus. Diabetes Educ 1992;18:407-10
25. Olefsky JM, Kolterman OG, Scarlett JA. Insulin action and resistance in obesity and noninsulin-dependent type II diabetes mellitus. Am J Physiol 1982;243:E15-30
26. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate gly-cemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013;36:2508-15
27. Janssen Pharmaceuticals, Inc. Prescribing information for InvokanaTM (cana-gliflozin). 2014. http://www.invokanahcp.com/prescribing-information.pdf. Accessed August 1, 2014
28. World Health Organization. 2014. Obesity and overweight. http://www.who. int/dietphysicalactivity/media/en/gsfs-obesity.pdf. Accessed August 1, 2014
29. Janssen Research & Development LLC. Canagliflozin (JNJ-28431754): Clinical Study Report Synopsis 28431754DIA3015. 2011. http://www.goo-gle.ca/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CB8QFjA A&url=http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR- JNJ-6051&studyid=859&filename=CR017227-CSR.pdf&ei=VCokVKHZO s2WyATD6oBw&usg=AFQjCNEvzGUhqf4mkPgMfknxICEI1vNPiw&bvm=bv. 76247554, d.aWw. Accessed August 1, 2014
30. Shire US Inc. Prescribing information for ProAmatine (midodrine). 2010. http://www.shire.com/shireplc/dlibrary/documents/Shire-ProAmatine Leaflet.pdf. Accessed August 1, 2014
31. Truven Health Analystics Inc. Red Book Online Search. 2014. http://www. micromedexsolutions.com/micromedex2/librarian. Accessed May 8, 2014
32. American Medical Association. CPT code/Relative Value Search. 2014. https://ocm.ama-assn.org/OCM/CPTRelativeValueSearch.do. Accessed May 15, 2014
33. Ward A, Alvarez P, Vo L, et al. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ 2014;17:176-83
34. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
35. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
36. United States Food and Drug Administration. FDA approves Invokana to treat type 2 diabetes. FDA News Release. 2013. Silver Spring, MD. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm. Accessed September 23, 2014
37. United States Food and Drug Administration. FDA approves new treatment for diabetes: first in a new class of diabetes drugs. FDA News Release. 2006. Silver Spring, MD. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108770.htm. Accessed September 23, 2014
38. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27-38
39. US Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Disease, National Diabetes Information Clearinghouse. National Diabetes Statistics, 2011. The National Diabetes Information Clearinghouse; Bethesda, MD. http://diabetes.niddk.nih.gov/dm/pubs/statistics/DM-Statistics-508.pdf. Accessed October 29, 2014
40. Oglesby AK, Secnik K, Barron J, et al. The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc 2006;4:1
41. Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm 2005;11:559-64
42. Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-19
43. Uk Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998;317:720
44. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Heal Aff 2003;(Suppl Web):W3-219-26
45. Wilson PWF, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162:1867-72
46. Raebel MA, Malone DC, Conner DA, et al. Health services use and health care costs of obese and nonobese individuals. Arch Intern Med 2004;164:2135-40
47. Quesenberry CP, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998;158:466-72
48. Thompson D, Brown JB, Nichols GA, et al. Body mass index and future healthcare costs: a retrospective cohort study. Obes Res 2001;9:210-18
49. Anderson JW, Kendall CWC, Jenkins DJA. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9
50. O'Keefe Jr JH, Miles JM, Harris WH, et al. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc 1999;74:171-80
51. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity: application to type 2 diabetes. Diabetes Care 1997;20:1744-66
52. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23:1499-504
53. Wing RR, Marcus MD, Salata R, et al. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. Arch Intern Med 1991;151:1334-40
54. Dilla T, Valladares A, Nicolay C, et al. Healthcare costs associated with change in Body Mass Index in patients with type 2 diabetes mellitus in Spain. Appl Health Econ Health Policy 2012;10:417-30
55. Wolf AM, Siadaty MIR, Yaeger B, et al. Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN). J Am Diet Assoc 2007;107:1365-73
56. Kalda R, Ratsep A, Lember M. Predictors of quality of life of patients with type 2 diabetes. Patient Prefer Adherence 2008;2:21-6
57. Gæde P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
58. Gæde P, Lund-Andersen H, Parving H-H, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358: 580-91
59. Eddy DM, Shah R. A simulation shows limited savings from meeting quality targets under the Medicare shared savings program. Heal Aff 2012;31 2554-62
60. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and costeffectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 2004;20(1 Suppl):S5-26
61. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 2003;26:3093-101
62. Willis M, Asseburg C, He J. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). J Med Econ 2013;16:1007-21
63. Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham heart study. Circulation 2009;119:243-50
64. Anderson RJ, Bahn GD, Moritz TE, et al. Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial. Diabetes Care 2011;34:34-8
65. Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999;159: 2004-9
66. Liu RH, Wharton S, Sharma AM, et al. Influence of a clinical lifestyle-based weight loss program on the metabolic risk profile of metabolically normal and abnormal obese adults. Obesity 2013;21:1533-9
67. Shi L, Ye X, Lu M, et al. Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes. Diabetes Care 2013;36:3297-304